ZD 6804
Latest Information Update: 09 Dec 1999
Price :
$50 *
At a glance
- Originator AstraZeneca
- Class Analgesics
- Mechanism of Action Prostaglandin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 09 Dec 1999 Discontinued-I for Pain in United Kingdom (Unknown route)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 09 Sep 1998 Phase-I clinical trials for Pain in United Kingdom (Unknown route)